Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$170.83
+0.5%
$176.53
$163.33
$251.99
$48.96B0.252.03 million shs3.07 million shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$38.55
0.0%
$38.86
$31.72
$44.67
$78.92B0.524.89 million shs4.92 million shs
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$379.00
+0.4%
$366.55
$289.98
$417.14
$91.18B1.491.46 million shs1.55 million shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$441.30
-0.5%
$454.50
$377.85
$519.88
$113.33B0.421.41 million shs3.62 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.00%+1.34%-0.99%-25.52%-26.91%
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.00%+1.45%-6.06%-0.69%+0.12%
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
0.00%+0.46%-0.60%+9.51%+17.97%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.00%+0.10%-0.39%-8.98%-5.85%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.926 of 5 stars
4.23.03.34.02.22.51.3
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.0306 of 5 stars
1.14.02.50.01.80.02.5
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
4.7492 of 5 stars
2.43.02.54.52.82.52.5
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
4.6805 of 5 stars
3.35.00.03.33.42.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.36
Hold$219.2228.33% Upside
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.10
Hold$37.38-3.04% Downside
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
2.74
Moderate Buy$395.714.41% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.54
Moderate Buy$511.6215.93% Upside

Current Analyst Ratings Breakdown

Latest HCA, GSK, VRTX, and BDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$376.00 ➝ $404.00
6/23/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$550.00
6/20/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$464.00 ➝ $460.00
6/17/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetSector Perform ➝ Sector Perform$423.00 ➝ $420.00
6/9/2025
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$355.00 ➝ $410.00
6/3/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$261.00 ➝ $241.00
6/3/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
6/2/2025
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/2/2025
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$366.00 ➝ $416.00
5/29/2025
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$320.00 ➝ $385.00
5/23/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$20.18B2.43$21.14 per share8.08$89.57 per share1.91
GSK PLC Sponsored ADR stock logo
GSK
GSK
$40.10B1.97$5.57 per share6.92$8.07 per share4.78
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$70.60B1.29$35.89 per share10.56$2.19 per share173.06
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$11.02B10.28N/AN/A$63.72 per share6.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.71B$5.2432.6010.921.297.28%15.99%7.36%8/7/2025 (Estimated)
GSK PLC Sponsored ADR stock logo
GSK
GSK
$3.29B$1.9419.878.291.359.89%48.82%11.15%7/30/2025 (Estimated)
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$5.76B$22.4916.8513.521.318.07%1,063.91%10.10%7/22/2025 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-$535.60M-$3.92N/A25.20N/A-8.91%-3.36%-2.42%7/30/2025 (Estimated)

Latest HCA, GSK, VRTX, and BDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/22/2025Q2 2025
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$6.20N/AN/AN/A$18.49 billionN/A
5/5/2025Q1 2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.29$4.06-$0.23$2.49$2.85 billion$2.77 billion
5/1/2025Q2 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.28$3.35+$0.07$1.06$5.35 billion$5.27 billion
4/30/2025Q1 2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.08$1.13+$0.05$1.00$7.52 billion$10.06 billion
4/25/2025Q1 2025
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$5.75$6.45+$0.70$6.45$18.26 billion$18.32 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.162.44%N/A79.39%53 Years
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.694.38%N/A87.11%N/A
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$2.880.76%N/A12.81%6 Years
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest HCA, GSK, VRTX, and BDX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42164.1%5/16/20255/16/20257/10/2025
4/29/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.042.02%6/9/20256/9/20256/30/2025
4/25/2025
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
quarterly$0.720.84%6/16/20256/16/20256/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.70
1.13
0.64
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.21
0.87
0.58
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
69.07
1.19
1.06
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.01
2.65
2.29

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
62.73%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.36%
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
1.30%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
77,000286.61 million285.58 millionOptionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
90,1002.05 billion1.84 billionOptionable
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
294,000240.57 million237.45 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,100256.80 million256.28 millionOptionable

Recent News About These Companies

Equities Analysts Offer Predictions for VRTX Q3 Earnings
Equities Analysts Set Expectations for VRTX Q2 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$170.83 +0.86 (+0.50%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$170.28 -0.55 (-0.32%)
As of 05:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

GSK stock logo

GSK NYSE:GSK

$38.54 -0.01 (-0.01%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$38.44 -0.11 (-0.27%)
As of 05:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

HCA Healthcare stock logo

HCA Healthcare NYSE:HCA

$379.00 +1.34 (+0.35%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$376.70 -2.30 (-0.61%)
As of 05:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$441.30 -2.10 (-0.47%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$442.77 +1.47 (+0.33%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.